Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Trial Profile

Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Pazopanib (Primary) ; Axitinib; Cabozantinib; Everolimus; Savolitinib; Sorafenib; Sunitinib; Temsirolimus
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms Spazo-2
  • Most Recent Events

    • 25 Apr 2018 Status changed to completed.
    • 10 Feb 2018 Results assessing outcomes of patients treated with pazopanib as first line in mRC according to gender, presented at the 2018 Genitourinary Cancers Symposium
    • 12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top